New agent reduces PTH levels in hemodialysis patients with secondary hyperparathyroidism

News
Article

New agent reduces PTH levels in hemodialysis patients with secondary hyperparathyroidism.

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!
Recent Videos
Related Content
FDA Approves Recurrent Respiratory Papillomatosis Treatment, Papzimeos

FDA Approves Recurrent Respiratory Papillomatosis Treatment, Papzimeos

Logan Lutton
August 17th 2025
Article

Read More

David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2

David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2

Briana Contreras
August 17th 2025
Podcast

Listen

Valeri Luzina-stock@adobe.com

Employers Project 10% Rise in Healthcare Costs for 2026

Denise Myshko
August 17th 2025
Article

Read More

Medication Prior Authorization Biggest Daily Challenge for 1 in 5 Prescribers, Survey Says

Medication Prior Authorization Biggest Daily Challenge for 1 in 5 Prescribers, Survey Says

Logan Lutton
August 17th 2025
Article

Read More

FDA Approves First Treatment for Chronic Inflammatory Lung Condition

FDA Approves First Treatment for Chronic Inflammatory Lung Condition

Denise Myshko
August 17th 2025
Article

Read More

FDA Approves Ajovy for Childhood Migraine Prevention

FDA Approves Ajovy for Childhood Migraine Prevention

Logan Lutton
August 17th 2025
Article

Read More

© 2025 MJH Life Sciences

All rights reserved.